Galectin Therapeutics

GALT • NASDAQ • Stock Fundamentals

Galectin Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Joel Lewis, with a market cap of $183.7M.

Market Cap$183.7M

Employees14.0

CEOJoel Lewis

CountryUnited States of America

Healthcare

Biotechnology

Most Recent EarningsMay 15, 2026 · 13 days agoQ1 2026

Next EarningsAug 13, 2026 · in 3 monthsQ2 2026

Financials

Based on Q1 2026 filing

Common questions about Galectin Therapeutics

Galectin Therapeutics (GALT) has a market capitalization of $183.7M and trades on NASDAQ.

Galectin Therapeutics has approximately 14 employees.